In tumor cells, activation of the MEK/ERK pathway increases the levels of serum interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), which is key for Treg conversion (Zdanov et al., 2016; Cheng et al., 2019). Here, TGFB1 is linked to neoplasm.